Lumito develops and markets innovative technology that opens new possibilities for advanced tissue sample analysis in research, drug development and digital pathology.
The Company’s patented SCIZYS® platform is based on upconverting nanoparticles (UCNPs), combining exceptionally high detection sensitivity with minimal background interference. This technology enables the identification and quantitative analysis of specific proteins in tissue – even at low levels that may be difficult to detect using conventional methods. The high signal stability and low background create the conditions for more detailed and reproducible tissue analysis.
SCIZYS® has the potential to contribute to the development from predominantly visual and semi-quantitative biomarker assessments towards more sensitive, objective and quantitative analysis. This can provide researchers with new tools to understand disease mechanisms, identify biomarkers and develop more individualized treatment strategies.
Lumito’s vision extends beyond today’s research applications. By unlocking more detailed information about biological processes, the Company aims to contribute to the development of precision medicine where better pharmaceuticals, improved diagnostics and more informed treatment decisions can ultimately lead to enhanced patient outcomes and a more efficient use of healthcare resources.
A research group in the Division of Atomic Physics and Laser Centre at Lund University proved the advantages of a medical application of upconverting nanoparticles (UCNP). Their research launched what would later become Lumito AB.